Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
August 03, 2023 16:30 ET
|
Cellectis Inc.
Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22),...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
August 01, 2023 16:30 ET
|
Cellectis Inc.
PARIS, 01 août 2023 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de...
Monthly information on share capital and company voting rights
August 01, 2023 16:30 ET
|
Cellectis Inc.
PARIS, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis présentera ses résultats financiers du deuxième trimestre 2023 le 3 août 2023
July 27, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, 27 juill. 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - Nasdaq : CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du...
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
July 27, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Cellectis nomme le docteur Cécile Chartier, Ph.D. à son conseil d’administration
July 12, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, 12 juill. 2023 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière...
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
July 12, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
July 05, 2023 16:30 ET
|
Cellectis Inc.
PARIS, 05 juill. 2023 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de...
Monthly information on share capital and company voting rights
July 05, 2023 16:30 ET
|
Cellectis Inc.
PARIS, July 05, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting...
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
June 28, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...